HRP20250056T1 - Anti-edb antitijela i antitijelo-lijek konjugati - Google Patents
Anti-edb antitijela i antitijelo-lijek konjugati Download PDFInfo
- Publication number
- HRP20250056T1 HRP20250056T1 HRP20250056TT HRP20250056T HRP20250056T1 HR P20250056 T1 HRP20250056 T1 HR P20250056T1 HR P20250056T T HRP20250056T T HR P20250056TT HR P20250056 T HRP20250056 T HR P20250056T HR P20250056 T1 HRP20250056 T1 HR P20250056T1
- Authority
- HR
- Croatia
- Prior art keywords
- antibody
- drug conjugate
- antigen
- binding fragment
- seq
- Prior art date
Links
- 239000000611 antibody drug conjugate Substances 0.000 title claims 24
- 229940049595 antibody-drug conjugate Drugs 0.000 title claims 24
- 239000000427 antigen Substances 0.000 claims 17
- 102000036639 antigens Human genes 0.000 claims 17
- 108091007433 antigens Proteins 0.000 claims 17
- 239000012634 fragment Substances 0.000 claims 17
- 239000003814 drug Substances 0.000 claims 6
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 claims 5
- 229940079593 drug Drugs 0.000 claims 5
- 108010044540 auristatin Proteins 0.000 claims 4
- 229940127089 cytotoxic agent Drugs 0.000 claims 4
- 239000002254 cytotoxic agent Substances 0.000 claims 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 4
- QAAFNSMAIAVCHE-BZLYQNAUSA-N (2s)-2-[(2-amino-2-methylpropanoyl)amino]-n-[(3r,4s,5s)-3-methoxy-1-[(2s)-2-[(1r,2r)-1-methoxy-2-methyl-3-oxo-3-[[(1s)-2-phenyl-1-(1,3-thiazol-2-yl)ethyl]amino]propyl]pyrrolidin-1-yl]-5-methyl-1-oxoheptan-4-yl]-n,3-dimethylbutanamide Chemical compound CC(N)(C)C(=O)N[C@@H](C(C)C)C(=O)N(C)[C@@H]([C@@H](C)CC)[C@H](OC)CC(=O)N1CCC[C@H]1[C@H](OC)[C@@H](C)C(=O)N[C@H](C=1SC=CN=1)CC1=CC=CC=C1 QAAFNSMAIAVCHE-BZLYQNAUSA-N 0.000 claims 3
- 102000039446 nucleic acids Human genes 0.000 claims 3
- 150000007523 nucleic acids Chemical class 0.000 claims 3
- 108020004707 nucleic acids Proteins 0.000 claims 3
- NFGXHKASABOEEW-UHFFFAOYSA-N 1-methylethyl 11-methoxy-3,7,11-trimethyl-2,4-dodecadienoate Chemical compound COC(C)(C)CCCC(C)CC=CC(C)=CC(=O)OC(C)C NFGXHKASABOEEW-UHFFFAOYSA-N 0.000 claims 2
- 102000016359 Fibronectins Human genes 0.000 claims 2
- 108010067306 Fibronectins Proteins 0.000 claims 2
- 206010028980 Neoplasm Diseases 0.000 claims 2
- 201000011510 cancer Diseases 0.000 claims 2
- 231100000599 cytotoxic agent Toxicity 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 2
- 208000035475 disorder Diseases 0.000 claims 2
- 239000003937 drug carrier Substances 0.000 claims 2
- 239000000203 mixture Substances 0.000 claims 2
- 229910052717 sulfur Inorganic materials 0.000 claims 2
- 125000004434 sulfur atom Chemical group 0.000 claims 2
- -1 wherein the antibody Proteins 0.000 claims 2
- 239000004475 Arginine Substances 0.000 claims 1
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- 206010009944 Colon cancer Diseases 0.000 claims 1
- 239000004472 Lysine Substances 0.000 claims 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims 1
- 208000029742 colonic neoplasm Diseases 0.000 claims 1
- 230000001268 conjugating effect Effects 0.000 claims 1
- 230000021615 conjugation Effects 0.000 claims 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 230000035772 mutation Effects 0.000 claims 1
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims 1
- 201000002523 pancreas lymphoma Diseases 0.000 claims 1
- 201000002528 pancreatic cancer Diseases 0.000 claims 1
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 102200033974 rs1555427497 Human genes 0.000 claims 1
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/05—Dipeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/07—Tetrapeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/68031—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being an auristatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/68033—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a maytansine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6843—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6889—Conjugates wherein the antibody being the modifying agent and wherein the linker, binder or spacer confers particular properties to the conjugates, e.g. peptidic enzyme-labile linkers or acid-labile linkers, providing for an acid-labile immuno conjugate wherein the drug may be released from its antibody conjugated part in an acidic, e.g. tumoural or environment
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662409081P | 2016-10-17 | 2016-10-17 | |
| EP17784700.1A EP3525828B1 (en) | 2016-10-17 | 2017-10-03 | Anti-edb antibodies and antibody-drug conjugates |
| PCT/IB2017/056093 WO2018073680A1 (en) | 2016-10-17 | 2017-10-03 | Anti-edb antibodies and antibody-drug conjugates |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20250056T1 true HRP20250056T1 (hr) | 2025-04-11 |
Family
ID=60117722
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20250056TT HRP20250056T1 (hr) | 2016-10-17 | 2017-10-03 | Anti-edb antitijela i antitijelo-lijek konjugati |
Country Status (22)
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3824906A1 (en) | 2016-12-21 | 2021-05-26 | Amgen Inc. | Anti-tnf alpha antibody formulations |
| CN113544155A (zh) * | 2018-12-12 | 2021-10-22 | 百时美施贵宝公司 | 经修饰用于转谷氨酰胺酶缀合的抗体、其缀合物以及方法和用途 |
| KR102614063B1 (ko) | 2020-12-24 | 2023-12-19 | 대화제약 주식회사 | 엑스트라도메인 b 피브로넥틴에 특이적으로 결합하는 신규한 항체 |
| CN112816453B (zh) * | 2021-02-09 | 2022-07-08 | 黑龙江大学 | 蛋白在预测药物性能上的应用 |
| JP2024525727A (ja) | 2021-07-14 | 2024-07-12 | ２セブンティ バイオ インコーポレイテッド | 抗体由来の結合ドメインに融合した操作されたｔ細胞受容体 |
| KR20250008809A (ko) | 2022-04-08 | 2025-01-15 | 리제너론 파마슈티칼스 인코포레이티드 | 다분할 수용체 및 신호전달 복합체 |
| WO2025011561A1 (en) * | 2023-07-10 | 2025-01-16 | Wuxi Xdc (Shanghai) Co., Ltd. | Antibody-drug conjugates and production thereof |
| WO2025149667A1 (en) | 2024-01-12 | 2025-07-17 | Pheon Therapeutics Ltd | Antibody drug conjugates and uses thereof |
Family Cites Families (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5663149A (en) | 1994-12-13 | 1997-09-02 | Arizona Board Of Regents Acting On Behalf Of Arizona State University | Human cancer inhibitory pentapeptide heterocyclic and halophenyl amides |
| US5952329A (en) | 1996-01-23 | 1999-09-14 | The General Hospital Corporation | Benzophenothiazine and benzoporphyrin dye combination photodynamic therapy of tumors |
| GB9610967D0 (en) | 1996-05-24 | 1996-07-31 | Cambridge Antibody Tech | Specific binding members,materials and methods |
| TWI259837B (en) | 1998-05-11 | 2006-08-11 | Eidgenossische Tech Hochscule | Specific binding molecules for scintigraphy, conjugates containing them and therapeutic method for treatment of angiogenesis |
| JP2003524018A (ja) | 2000-02-24 | 2003-08-12 | アイトゲネーシシェ テクニシェ ホッホシューレ チューリッヒ | フィブロネクチンのｅｄ‐ｂドメインに特異的な抗体、前記抗体を含む複合体、および血管形成を検出および治療するためのその使用 |
| DK1257297T3 (da) * | 2000-02-24 | 2006-11-20 | Philogen Spa | Sammensætninger og fremgangsmåder til behandling af angiogenese i patologiske læsioner |
| US7498029B2 (en) | 2001-05-01 | 2009-03-03 | The General Hospital Corporation | Photoimmunotherapies for cancer using combination therapies |
| US6997863B2 (en) | 2001-07-25 | 2006-02-14 | Triton Biosystems, Inc. | Thermotherapy via targeted delivery of nanoscale magnetic particles |
| RU2352582C2 (ru) * | 2002-01-03 | 2009-04-20 | Шеринг Акциенгезельшафт | Конъюгаты, содержащие антитело, специфическое для ed-в-домена фибронектина, и их применение для обнаружения и лечения опухолей |
| PT1483297E (pt) | 2002-03-11 | 2010-03-29 | Philogen Spa | Anticorpos derivados de anti-ed-b l19 e direccionamento para a vasculatura tumoral |
| PL374528A1 (en) * | 2002-07-31 | 2005-10-31 | Schering Aktiengesellschaft | New effector conjugates, process for their production and their pharmaceutical use |
| WO2006113546A2 (en) | 2005-04-15 | 2006-10-26 | Neogenix Oncology, Inc. | Recombinant monoclonal antibodies and corresponding antigens for colon and pancreatic cancers |
| ATE459648T1 (de) * | 2005-05-11 | 2010-03-15 | Philogen Spa | Fusionsprotein von antikörper l19 gegen fibronectin ed-b und interleukin 12 |
| DK1931702T3 (da) | 2005-10-05 | 2013-04-15 | Commw Scient Ind Res Org | Silkeproteiner |
| EP1842553A1 (en) | 2006-04-07 | 2007-10-10 | Bayer Schering Pharma Aktiengesellschaft | Combination of an anti-EDb fibronectin domain antibody/IL2 fusion protein and a further small molecule |
| EP2015775B1 (en) * | 2006-05-03 | 2011-06-01 | Bayer Schering Pharma Aktiengesellschaft | Combination of an anti edb fibronectin domain antibody l19-sip and an anti-egfr antibody |
| TWI412367B (zh) * | 2006-12-28 | 2013-10-21 | Medarex Llc | 化學鏈接劑與可裂解基質以及其之綴合物 |
| BRPI0809989B8 (pt) | 2007-04-02 | 2021-05-25 | Philogen Spa | usos de um anticorpo ou fragmento de ligação a antígeno do mesmo que se liga a isoforma extradomínio-a (ed-a) de fibronectina e/ou ao ed-a de fibronectina |
| US20100183506A1 (en) | 2007-07-25 | 2010-07-22 | Dario Neri | Antigen associated with lung cancers and lymphomas |
| ATE548052T1 (de) * | 2008-01-17 | 2012-03-15 | Philogen Spa | Kombination aus einem anti-edb-fibronectin- antikörper-il-2-fusionsprotein und einem b-zellen bindenden molekül, b-zellen-vorläufern und/oder deren krebserregendem gegenspieler |
| CA2749501C (en) * | 2009-02-13 | 2017-01-10 | Immunomedics, Inc. | Immunoconjugates with an intracellularly-cleavable linkage |
| ES2640981T3 (es) | 2009-08-05 | 2017-11-07 | Philogen S.P.A. | Selección como diana de neovasculatura de médula ósea |
| AU2010285071A1 (en) | 2009-08-17 | 2012-02-02 | Roche Glycart Ag | Targeted immunoconjugates |
| BR112013007160A2 (pt) | 2010-09-29 | 2016-06-14 | Philogen Spa | ligante tiazolidina para a conjugação de fármacos a anticorpos |
| CA2813411C (en) | 2010-11-05 | 2016-08-02 | Rinat Neuroscience Corporation | Engineered polypeptide conjugates and methods for making thereof using transglutaminase |
| EA201892619A1 (ru) * | 2011-04-29 | 2019-04-30 | Роше Гликарт Аг | Иммуноконъюгаты, содержащие мутантные полипептиды интерлейкина-2 |
| ES2657014T3 (es) | 2011-11-17 | 2018-03-01 | Pfizer Inc. | Péptidos citotóxicos y conjugados de fármaco anticuerpo de los mismos |
| CA3111357A1 (en) | 2011-12-23 | 2013-06-27 | Pfizer Inc. | Engineered antibody constant regions for site-specific conjugation and methods and uses therefor |
| WO2014124316A2 (en) * | 2013-02-08 | 2014-08-14 | Irm Llc | Specific sites for modifying antibodies to make immunoconjugates |
| WO2014174105A1 (en) * | 2013-04-25 | 2014-10-30 | Philochem Ag | Antibody-drug conjugates |
| RU2669807C2 (ru) * | 2014-01-27 | 2018-10-16 | Пфайзер Инк. | Бифункциональные цитотоксические агенты |
| WO2015114166A2 (en) * | 2014-02-03 | 2015-08-06 | Philochem Ag | Targeted drug conjugates |
| CN106456798B (zh) | 2014-04-25 | 2021-02-12 | 瑞纳神经科学公司 | 具有高药物负载的抗体-药物缀合物 |
| CA2949032A1 (en) | 2015-11-30 | 2017-05-30 | Pfizer Inc. | Site specific her2 antibody drug conjugates |
| TWI637966B (zh) * | 2015-11-30 | 2018-10-11 | 輝瑞股份有限公司 | 用於部位專一性接合之抗體和抗體片段 |
-
2017
- 2017-10-03 IL IL310865A patent/IL310865A/en unknown
- 2017-10-03 FI FIEP17784700.1T patent/FI3525828T3/fi active
- 2017-10-03 RU RU2019111303A patent/RU2758632C2/ru active
- 2017-10-03 CA CA3040423A patent/CA3040423A1/en active Pending
- 2017-10-03 ES ES17784700T patent/ES3007557T3/es active Active
- 2017-10-03 EP EP17784700.1A patent/EP3525828B1/en active Active
- 2017-10-03 HU HUE17784700A patent/HUE070615T2/hu unknown
- 2017-10-03 RS RS20250049A patent/RS66524B1/sr unknown
- 2017-10-03 HR HRP20250056TT patent/HRP20250056T1/hr unknown
- 2017-10-03 CN CN202310030234.XA patent/CN116251196A/zh active Pending
- 2017-10-03 SG SG11201903400WA patent/SG11201903400WA/en unknown
- 2017-10-03 EP EP25168356.1A patent/EP4635516A2/en active Pending
- 2017-10-03 PT PT177847001T patent/PT3525828T/pt unknown
- 2017-10-03 LT LTEPPCT/IB2017/056093T patent/LT3525828T/lt unknown
- 2017-10-03 JP JP2019520386A patent/JP7039577B2/ja active Active
- 2017-10-03 MX MX2019004434A patent/MX2019004434A/es unknown
- 2017-10-03 DK DK17784700.1T patent/DK3525828T3/da active
- 2017-10-03 IL IL266112A patent/IL266112B2/en unknown
- 2017-10-03 WO PCT/IB2017/056093 patent/WO2018073680A1/en not_active Ceased
- 2017-10-03 AU AU2017344440A patent/AU2017344440B2/en active Active
- 2017-10-03 CN CN201780078019.XA patent/CN110087691B/zh active Active
- 2017-10-03 KR KR1020197013908A patent/KR102338660B1/ko active Active
- 2017-10-03 SI SI201731585T patent/SI3525828T1/sl unknown
- 2017-10-03 PL PL17784700.1T patent/PL3525828T3/pl unknown
- 2017-10-03 US US16/342,275 patent/US20190269791A1/en not_active Abandoned
- 2017-10-03 EP EP24223209.8A patent/EP4617283A2/en active Pending
-
2019
- 2019-04-15 MX MX2024003463A patent/MX2024003463A/es unknown
-
2020
- 2020-10-26 AU AU2020260375A patent/AU2020260375B2/en active Active
-
2021
- 2021-11-24 JP JP2021190070A patent/JP7383682B2/ja active Active
-
2023
- 2023-02-09 US US18/166,774 patent/US11833216B2/en active Active
- 2023-10-23 US US18/492,055 patent/US20240181071A1/en active Pending
- 2023-10-23 US US18/492,348 patent/US20240156977A1/en active Pending
- 2023-11-08 JP JP2023191037A patent/JP2023184697A/ja active Pending
- 2023-12-04 US US18/528,539 patent/US20240261423A1/en active Pending
-
2024
- 2024-02-23 AU AU2024201216A patent/AU2024201216A1/en active Pending
-
2025
- 2025-09-03 JP JP2025146227A patent/JP2025175010A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20250056T1 (hr) | Anti-edb antitijela i antitijelo-lijek konjugati | |
| RU2016129894A (ru) | Ковалентно связанные конъюгаты хеликар-антитело против хеликара и их применения | |
| JP2015531750A5 (cg-RX-API-DMAC7.html) | ||
| RU2016111131A (ru) | Способы конъюгации сайт-специфических антител и композиции | |
| HRP20210326T1 (hr) | Konjugati protutijela protiv cmet s lijekom i postupci njihove upotrebe | |
| JP2016531915A5 (cg-RX-API-DMAC7.html) | ||
| JP2018509908A5 (cg-RX-API-DMAC7.html) | ||
| HRP20231609T1 (hr) | Konjugati lijeka koji sadrže antitijela protiv klaudina 18.2 | |
| HRP20201747T1 (hr) | Bispecifične antigen vezujuće molekule koje aktiviraju t stanice, protiv folr1 i cd3 | |
| FI3558390T3 (fi) | Amanitinivasta-ainekonjugaatit | |
| JP2012522512A5 (cg-RX-API-DMAC7.html) | ||
| HRP20200721T1 (hr) | Aktivirajuća anti-cd166 antitijela i postupci njihove uporabe | |
| JP2016536020A5 (cg-RX-API-DMAC7.html) | ||
| HRP20200032T1 (hr) | Antitijelo lijek konjugati | |
| JP2016523810A5 (cg-RX-API-DMAC7.html) | ||
| HRP20201091T1 (hr) | Protutijela anti-axl | |
| SI2906296T1 (en) | Pyrrolobenzodiazepine-antibody conjugates | |
| HRP20220172T1 (hr) | Protutijela protiv cd71 koja se mogu aktivirati, te postupci njihove uporabe | |
| JP2019534706A5 (cg-RX-API-DMAC7.html) | ||
| JP2012522513A5 (cg-RX-API-DMAC7.html) | ||
| HRP20180015T1 (hr) | Anti-mezotelinski imunokonjugati i njihova uporaba | |
| JP2014139173A5 (cg-RX-API-DMAC7.html) | ||
| JP2020526584A5 (cg-RX-API-DMAC7.html) | ||
| IL276514B1 (en) | Glypican 3 antibodies and conjugates thereof | |
| JP2016503295A5 (cg-RX-API-DMAC7.html) |